CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 460 enrolled
Drug / intervention
Multivalent +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03512288
NCT03512288Phase 2Completed
CompareCT.gov

A PHASE 2, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

Pfizer·interventional·Posted Apr 30, 2018·Updated Mar 2, 2021

In Brief

A Phase 2 clinical trial evaluating Multivalent and 13vPnC for Pneumococcal Infections. Completed, enrolled 460 participants across 39 sites.

Detailed Summary

A Phase 2, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Infections
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 30, 2018
Enrollment StartApr 16, 2018
Primary CompletionFeb 11, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 8.2 years ago

Interventions

Multivalentbiological

Pneumococcal conjugate vaccine

13vPnCbiological

Pneumococcal conjugate vaccine